This is a disappointing valuation. AE37 breast cancer alone was valued at $300M 10 years ago. Now we have 10 year data, added Covid potential vaccine, contract with Bintai for at least $150M, a contract with China for at least $1B, prostate potential, melanoma potential, etc and we get a value of $500M. They waited this long for this valuation? Very disappointed. If they put out the 400,300,000 shares, you are looking at $1.25 NGIO value. I don’t see Joe lowering the share count, as suggested here, since he wants that big piggy bank, the same way he used $2.50 GNBT shares. I guess he will tell us in February.